30
JUN
2016

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

Posted By :
Comments : Off
Progress Also Reported On Additional Nasdaq Compliance Issue   BETHESDA, MD, June 30, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced it had filed an 8-K today relating to two outstanding Nasdaq issues, including progress on a remediation plan relating to certain prior stock issuances. On June 24, 2016, Northwest...
Read More
13
JUN
2016

NW Bio Announces Scientific Advisory Board

Posted By :
Comments : Off
Leading Experts in Immunotherapies and Oncology From Both the US and Europe   BETHESDA, MD, June 13, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe. The Company anticipates that the SAB...
Read More
02
MAY
2016

NW Bio Announces Operations Updates

Posted By :
Comments : Off
New Developments Relating to Phase I and II Trials, Scientific Advisory Board and Nasdaq Compliance   BETHESDA, MD, May 2, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance. The Company has reached...
Read More
29
FEB
2016

NW Bio Announces Registered Direct Offering Of Up To $27.6 Million With Existing Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., February 29, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with current institutional investors for a registered direct offering with gross proceeds of up to approximately $27.6 million, assuming exercise in full of the overallotment option described...
Read More
25
JAN
2016

NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise

Posted By :
Comments : Off
BETHESDA, Md., January 25, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors.  Neither Ms. Bayh nor Ambassador Black has worked with the Company previously. Ms. Bayh brings to NW...
Read More